Since its introduction a few years ago, the cancer drug imatinib has given patients with chronic myelogenous leukemia an unprecedented chance at long-term survival. But studies of the drug in people and mice reveal an unexpected risk of heart failure lurking beneath imatinib’s benefits.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.